The Feasibility of 64Cu-PSMA I&T PET for Prostate Cancer-Reference-Cited by-同舟云学术

The Feasibility of 64Cu-PSMA I&T PET for Prostate Cancer

Published:2021-01-12 Issue: Volume: Page:
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Lee Chul-Hee¹²³,Lim Ilhan¹,Woo Sang-Keun¹⁴,Kim Kwang Il⁴,Lee Kyo Chul⁴,Song Kanghyon⁵,Choi Chang Woon¹,Lim Sang Moo¹

Affiliation:

1. Department of Nuclear Medicine, Korea Cancer Centre Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea.

2. Division of Applied RI, Research Institute of Radiological & Medical Sciences, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea.

3. Department of Urology, Korea Cancer Centre Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea.

4. Department of Nuclear Medicine, Seoul. National University Hospital, Seoul, Republic of Korea.

5. Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2020.4189

Reference42 articles.

1. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer

2. Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis

3. Molecular markers of prostate cancer

4. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression

5. Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer;Diagnostics;2023-08-11

2. Dual-Time-Point Posttherapy¹⁷⁷Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients’ Outcome;Journal of Nuclear Medicine;2023-07-06

3. 67Ga-PSMA I&T for Radioguided Surgery of Lymph Node Metastases in Patients With Biochemical Recurrence of Prostate Cancer;Clinical Nuclear Medicine;2023-05-05

4. ¹⁷⁷Lu–Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer;Radiology;2023-02-01

5. Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization;Nuclear Medicine and Molecular Imaging;2022-08-20